BÖTTIGER et al., 1992 - Google Patents
Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidineBÖTTIGER et al., 1992
- Document ID
- 5526553802168473960
- Author
- BÖTTIGER D
- PUTKONEN P
- ÖBERG B
- Publication year
- Publication venue
- AIDS research and human retroviruses
External Links
Snippet
The aim of this study was to determine the usefulness of human immunodeficiency virus type 2 (HIV-2) for in vivo evaluation of antiviral drugs in monkeys and to study if prophylactic treatment with 3ḿ-fluorothymidine (FLT) could prevent infection against a low challenge …
- 208000005721 HIV Infections 0 title abstract description 33
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amadori et al. | B-cell activation and HIV-1 infection: deeds and misdeeds | |
| Polis et al. | Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria | |
| Jiang et al. | SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89. 6P in macaques | |
| Niu et al. | Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections | |
| Marlink | Lessons from the second AIDS virus, HIV-2 | |
| Karpas et al. | Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. | |
| Nara et al. | Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses | |
| Joag | Primate models of AIDS | |
| QUESADA-ROLANDER et al. | Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope | |
| Hom et al. | Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells | |
| BÖTTIGER et al. | Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine | |
| JOHNSON et al. | Long-term observations of human immunodeficiency virus-infected chimpanzees | |
| Emau et al. | Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention | |
| Putkonen et al. | Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission | |
| WYAND | The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines | |
| Ruprecht et al. | Vaccination with a live retrovirus: the nature of the protective immune response. | |
| Van Rompay et al. | Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection | |
| MORROW et al. | Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment | |
| Macé et al. | Restriction of HIV-1 replication in promonocytic cells: a role for IFN-α | |
| Hoover et al. | Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) | |
| Tanabe-Tochikura et al. | Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro | |
| Gartner et al. | Adaptation of HIV‐1 to pigtailed macaques | |
| US5519028A (en) | Antiviral preparations | |
| RU2060032C1 (en) | Method of inhibition of human immunodeficiency virus activity in experiment in vivo | |
| US5888726A (en) | Pertussis toxin induced lymphocytosis |